Medical device startup consulting resources to grow your early stage lifescience business

Blog – Resources for Lifescience Start-ups

The Strategy Inc. blog includes valuable information for lifescience startups seeking industry guidance. Does your innovation improve patient outcomes or improve healthcare operations to make hospitals more efficient?  Emerging lifescience entrepreneurs seek to ensure that the technologies they are developing will effectively address an unmet clinical need and track successful commercialization. Articles on this page focus on different aspects of development and cover the predictors of a clinician’s willingness to pay for an innovation, the expanding role of Key Opinion Leaders in innovation development and other aspects of the multifaceted process. These posts aim to provide guidance for the emerging entrepreneurs.  

This page will be updated with expanded articles to support the development process for lifescience executives prioritizing resources and medical device consulting. Future articles are planned for “How to Determine the Valuation of a Preclinical Lifescience Innovation”, “Identifying Your Platform Technology Target Indication for Use”, “Projecting Adoption Curves for Early Stage Lifescience Technology” and more. If you have a specific topic that you would like to see included, send a message to, and we will let you know when that article is posted. 

An Update on Neuromodulation: Expanded indications, device miniaturization and advances in glial cell stimulation drive significant market growth

By |June, 2021|

The neuromodulation market is a rapidly evolving segment of the medical device industry, expanding into emerging applications. From shifts in strategic investment to insights in technological advancements, this article covers recent sales trends and projections, neuromodulation VC fundings, as well as explores the emerging neurostimulation device […]

Metrics are showing that rebound will emerge in terms of technology adoption, investments and innovation

By |July, 2020|

In the next phase of the global pandemic, lifescience leaders and investors want to confirm the resiliency of the healthcare sector. In a time of questions, how do we continue to progress and where should we focus? As we journey through this season, speculations and comparisons emerge for what the healthcare market will look like on the other side of the global COVID-19 pandemic, and how medical device and biotechnology investment and hospital purchasing will compare to life before.

Eight Important Predictors of Clinical Adoption: How to Determine Clinician Willingness to Pay for Lifescience Innovation—Price Versus Features

By |July, 2017|

As originally posted on LinkedIn by Ron Trahan, Medtech Journalist

What distinguishes between a technology physicians say they want and one they are willing to pay for? Furthermore, how do you determine those features that would be nice to have versus those that raise the value of your technology? Successful commercialization relies on the balance of a number of market factors and careful planning. When considering the strategic distribution of your R&D and marketing resources the voice of the customer is essential.

How to Determine Projected Adoption of Your Preclinical Life Science Technology that Changes the Standard of Care

By |July, 2017|

As originally posted on LinkedIn by Ron Trahan, Medtech Journalist

Medical device executives desire to achieve successful commercialization, yielding a multimillion $/€/¥ exit while delivering clinical value to patients who benefit. To achieve these objectives, entrepreneurs have ever-changing hurdles to conquer. With so much at stake, how is it possible to identify the indication for use with the highest potential for successful commercialization, and to predict adoption early in the development process?

The Changing Role of KOLs for Lifescience Innovation Development

By |July, 2017|

As originally posted on LinkedIn by Ron Trahan, Medtech Journalist

Lifescience companies rely on selected Key Opinion Leaders (KOLs) to build advocacy for their technology, for clinical guidance on practice patterns, and for increased understanding of competitive technology usage and market trends. However, in the current era of comparative clinical effectiveness driving technology adoption, best practice roles for KOLS are expanding.

Go to Top